{"id":69252,"date":"2026-07-02T15:19:20","date_gmt":"2026-07-02T07:19:20","guid":{"rendered":"https:\/\/flcube.com\/?p=69252"},"modified":"2026-07-02T15:19:21","modified_gmt":"2026-07-02T07:19:21","slug":"jingxin-pharmaceutical-secures-nmpa-approval-for-chinas-first-generic-cariprazine-in-schizophrenia-capturing-market-opportunity-as-reference-product-remains-unlaunched","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69252","title":{"rendered":"Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia \u2013 Capturing Market Opportunity as Reference Product Remains Unlaunched"},"content":{"rendered":"\n

Jingxin Pharmaceutical<\/strong> (SHE: 002020<\/a>) announced that China’s National Medical Products Administration (NMPA)<\/strong> has approved the marketing<\/strong> of cariprazine<\/strong> (1.5 mg and 3 mg) for the treatment of adult schizophrenia<\/strong>. The product represents the first generic version approved in China<\/strong> and has been deemed to have passed the consistency evaluation<\/strong>, positioning Jingxin to capture significant market share in the absence of the reference listed drug in the Chinese market.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Type<\/strong><\/td>Marketing authorization<\/td><\/tr>
Product<\/strong><\/td>Cariprazine tablets (1.5 mg and 3 mg)<\/td><\/tr>
Indication<\/strong><\/td>Adult schizophrenia<\/td><\/tr>
Generic Status<\/strong><\/td>First generic approved in China<\/td><\/tr>
Consistency Evaluation<\/strong><\/td>Passed (bioequivalent to reference product)<\/td><\/tr>
Reference Product Status<\/strong><\/td>Not launched in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Pharmacological Mechanism<\/h2>\n\n\n\n

Cariprazine \u2013 Atypical Antipsychotic<\/h3>\n\n\n\n